Sergiu Pasca

Cluj-napoca, CJ, Romania

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 89 publications

Deleterious mitochondrial heteroplasmy drives high-risk clonal hematopoiesis and hematological malignancy.

Deleterious mitochondrial heteroplasmy drives high-risk clonal hematopoiesis and hematological malignancy.

Journal: medRxiv : the preprint server for health sciences
Published: July 03, 2026

A plasma-based DNA test for quantification of disease burden in acute myeloid leukemia patients undergoing bone marrow transplantation.

A plasma-based DNA test for quantification of disease burden in acute myeloid leukemia patients undergoing bone marrow transplantation.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: April 14, 2026

A plasma-based DNA test for quantification of disease burden in acute myeloid leukemia patients undergoing bone marrow transplantation.

A plasma-based DNA test for quantification of disease burden in acute myeloid leukemia patients undergoing bone marrow transplantation.

Journal: medRxiv : the preprint server for health sciences
Published: February 23, 2026

Evolution to complex karyotype disease in mono-allelic TP53-mutated myelodysplastic syndrome/acute myeloid leukemia: a cohort study.

Evolution to complex karyotype disease in mono-allelic TP53-mutated myelodysplastic syndrome/acute myeloid leukemia: a cohort study.

Journal: Haematologica
Published: February 15, 2026

Mitochondrial heteroplasmy is a risk factor for the development of chronic lymphocytic leukemia.

Mitochondrial heteroplasmy is a risk factor for the development of chronic lymphocytic leukemia.

Journal: Nature communications
Published: April 04, 2025

CCRL2 promotes the interferon-γ signaling response in myeloid neoplasms with erythroid differentiation and mutated TP53.

CCRL2 promotes the interferon-γ signaling response in myeloid neoplasms with erythroid differentiation and mutated TP53.

Journal: bioRxiv : the preprint server for biology
Published: March 10, 2025

C-C motif chemokine receptor-like 2 promotes the interferon-γ signaling response in myeloid neoplasms with erythroid differentiation and mutated TP53.

C-C motif chemokine receptor-like 2 promotes the interferon-γ signaling response in myeloid neoplasms with erythroid differentiation and mutated TP53.

Journal: Haematologica
Published: March 04, 2025

Comprehensive characterization of human bone marrow microenvironment shows age-related changes.

Comprehensive characterization of human bone marrow microenvironment shows age-related changes.

Journal: Haematologica
Published: March 03, 2025

Inferred clonal hematopoiesis from tumor DNA sequencing among men with prostate cancer: correlation with somatic tumor alterations and outcomes.

Inferred clonal hematopoiesis from tumor DNA sequencing among men with prostate cancer: correlation with somatic tumor alterations and outcomes.

Journal: The oncologist
Published: August 23, 2024

Mitochondrial heteroplasmy improves risk prediction for myeloid neoplasms.

Mitochondrial heteroplasmy improves risk prediction for myeloid neoplasms.

Journal: Nature communications
Published: May 08, 2024

Single low-dose decitabine as frontline therapy of acute myeloid leukaemia, with venetoclax salvage.

Single low-dose decitabine as frontline therapy of acute myeloid leukaemia, with venetoclax salvage.

Journal: Journal of cellular and molecular medicine
Published: December 26, 2023

Association of PARP inhibitor treatment on the prevalence and progression of clonal hematopoiesis in patients with advanced prostate cancer.

Association of PARP inhibitor treatment on the prevalence and progression of clonal hematopoiesis in patients with advanced prostate cancer.

Journal: The Prostate
Published: October 30, 2023
Showing 1-12 of 89

Last Updated: 09/26/2026